# EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial

> **NCT04891133** · PHASE2,PHASE3 · TERMINATED · sponsor: **Oslo University Hospital** · enrollment: 290 (actual)

## Conditions studied

- COVID-19
- Emerging Infectious Disease

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04891133
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-03
- **Primary completion:** 2022-12-15
- **Final completion:** 2023-01-23
- **Target enrollment:** 290 (ACTUAL)
- **Why stopped:** The trial was stopped prematurely due to external evidence that arose during the study period showing that the IMP, baricitinib, was not effective in the primary study population.
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891133, "EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04891133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*